Consider a contrarian investment in "unloved" alcohol sector stocks, which are trading at depressed levels after years of underperformance. Companies like Diageo (DEO) and AB InBev (BUD) represent a potential value play for investors willing to bet against negative consumer trends. For long-term growth, view Tesla (TSLA) as an AI and robotics company, not just an automaker. The Optimus humanoid robot is a key future catalyst, so monitor progress towards its targeted Q1 2026 mass production goal. Lastly, keep the potential for a future "megacorp" IPO led by SpaceX, which could include xAI and Twitter/X, on your long-term investment radar.

xAI (Private)

• Fundraising: Successfully raised $20 billion in a Series A round, significantly more than the rumored $15 billion. This was achieved despite initial skepticism about the company's valuation and lack of enterprise adoption compared to competitors.
• Product (Grok): The company's AI, Grok, has shown promise and is used by the podcast hosts, but has also been the source of some controversy due to its outputs.
• Synergy with other Elon Musk companies: The discussion highlights a powerful potential integration between Musk's ventures:
  • AI chip design from Tesla.
  • AI models trained by xAI.
  • Deployment via Starlink satellites launched by SpaceX rockets.
• Potential Corporate Structure: The hosts speculate that the "most entertaining outcome" would be for the privately-held SpaceX to acquire xAI and Twitter/X before a potential future IPO. This would create a single, publicly-traded "Elon Inc. Megacorp."

Takeaways

• Direct Investment: As a private company, xAI is not available for public investment.
• Future IPO Watch: The key takeaway is the potential for a massive future IPO of a combined entity, likely led by SpaceX and including xAI and Twitter/X. This would be a unique investment opportunity, offering exposure to space exploration, AI, and social media in a single stock.
• Halo Effect on Tesla: The development of xAI and its potential integration with Tesla's AI chip and robotics divisions could be a significant long-term catalyst for Tesla (TSLA) stock.

Tesla (TSLA)

• Optimus Robot: The mass production audit for the Optimus V3 humanoid robot has been completed.
  • Timeline: The company is targeting mass production in Q1 2026.
  • Production Goals: A capacity of 50,000 to 100,000 units is targeted by the end of 2026.
  • Price: The hosts speculate the price could be $50,000+ per unit.
• Skepticism: The podcast notes that some experts, like George Hotz, believe the timeline for capable humanoid robots is closer to a decade away. However, even as a marketing tool in showrooms, Optimus is seen as having value.
• Historical Context: The hosts recall Elon Musk's 2018 proposal to take Tesla private at $420/share when it was worth $64 billion. The stock has increased 22x since that time.

Takeaways

• Long-Term Growth Vector: The Optimus robot represents a massive potential growth area for Tesla beyond electric vehicles. While the timeline is uncertain and subject to debate, progress in this area could significantly impact the company's future valuation.
• Monitor Production Milestones: Investors should watch for updates on the Q1 2026 production target for Optimus, as hitting these milestones would be a major positive catalyst.
• More Than a Car Company: The discussion reinforces the narrative that Tesla is an AI and robotics company, not just an automaker. Its role in the potential "Elon Inc. Megacorp" further solidifies this view.

Alcohol Sector Stocks

• Performance: The podcast highlights a discussion about "unloved booze stocks," noting that the sector has dramatically underperformed the broader market. Over the last five years, the S&P 500 is up 96%, while major alcohol stocks are down significantly.
  • Boston Beer (SAM): Down 80%
  • Remy Cointreau: Down 75%
  • Pernod Ricard: Down 50%
  • Diageo (DEO): Down 38%
  • Heineken: Down 21%
  • AB InBev (BUD): Down 4%
• Headwinds: Reasons cited for the poor performance include the rising popularity of cannabis, the effects of weight-loss drugs like Ozempic (which can reduce cravings), and increased health consciousness among consumers.
• Contrarian View: The discussion, referencing a Wall Street Journal article, suggests that "in a market with few bargains, booze looks interesting." January can be a good time to buy "unloved" stocks that were sold off at the end of the prior year.

Takeaways

• Contrarian/Value Play: The alcohol sector represents a potential value or contrarian investment theme. These stocks are trading at depressed levels after years of underperformance.
• High Risk: Investors should be aware of the significant risks. The negative trends impacting the sector (cannabis competition, health trends) may be long-term, structural changes rather than temporary setbacks.
• Further Research Needed: This could be an interesting area for investors looking for bargains, but it requires careful consideration of whether the current low prices adequately compensate for the industry's challenges.

OpenAI (Private)

• New Product Launch: OpenAI has launched ChatGPT Health, a dedicated and private feature for health-related conversations.
• Market Size: The launch is supported by data showing that 20% of all ChatGPT queries are health-related, with over 40 million people using it for health questions daily.
• Functionality: ChatGPT Health allows users to connect their medical records and data from apps like Apple Health and Peloton to receive more personalized support for meal plans, exercise routines, and preparing for doctor's appointments.
• Strategy: This move shows OpenAI's strategy of building specialized, vertical applications on top of its general AI models, targeting high-value industries like healthcare. The hosts speculate that legal services could be the next vertical.

Takeaways

• Vertical Integration: OpenAI is not just a foundational model company; it is actively competing in specific application areas. This strategy could create significant new revenue streams and increase its competitive moat.
• Future IPO Value: The successful expansion into verticals like health makes a potential future IPO of OpenAI more compelling, as it would offer investors exposure to both the core AI technology and its direct application in lucrative industries.
• Competitive Threat: Companies building "wrapper" applications on top of OpenAI's models, especially in the health space, now face direct competition from the platform itself.

Other Mentions

• SpaceX (Private): Discussed as the potential vehicle for a "megacorp" IPO that would include xAI and Twitter/X. The company has raised $12 billion in its history, a figure dwarfed by xAI's recent $20 billion round. The primary investment insight is to watch for news of this potential combined IPO.

• Anthropic (Private): A major AI competitor whose high valuation (rumored $350 billion) serves as a benchmark for the private AI market. Its performance and fundraising activities are indicators of the overall health and investor appetite for the AI sector.

• Razer (Gaming Hardware): The discussion of its Project Ava AI companion concept highlights the company's innovation and push into AI-integrated hardware. While speculative, success in this area could open up a new growth category for the company beyond traditional gaming peripherals.

• Apple (AAPL): Its integration with ChatGPT Health reinforces the power of its ecosystem. The hosts' trust in Apple's design ("If Apple made your thermostat, it would be good") underscores its strong brand reputation, a key advantage for any future product expansions, particularly in the smart home space.

• Peloton (PTON): Its inclusion as a launch partner for ChatGPT Health is a small positive, providing brand visibility and deeper integration into the digital health ecosystem.